Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.

Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd.

Otol Neurotol. 2012 Aug;33(6):1046-52. doi: 10.1097/MAO.0b013e31825e73f5.

PMID:
22805104
2.

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E.

N Engl J Med. 2009 Jul 23;361(4):358-67. doi: 10.1056/NEJMoa0902579. Epub 2009 Jul 8.

3.

Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.

Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG 2nd.

Otol Neurotol. 2010 Sep;31(7):1135-43. doi: 10.1097/MAO.0b013e3181eb328a.

4.

Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.

Hochart A, Gaillard V, Baroncini M, André N, Vannier JP, Vinchon M, Dubrulle F, Lejeune JP, Vincent C, Nève V, Sudour Bonnange H, Bonne NX, Leblond P.

J Neurooncol. 2015 Sep;124(2):229-36. doi: 10.1007/s11060-015-1828-8. Epub 2015 May 29.

PMID:
26022982
5.

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.

Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J.

Neuro Oncol. 2010 Jan;12(1):14-8. doi: 10.1093/neuonc/nop010. Epub 2009 Oct 20.

6.

Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.

Fisher LM, Doherty JK, Lev MH, Slattery WH.

Otol Neurotol. 2009 Sep;30(6):835-41. doi: 10.1097/MAO.0b013e3181b2364c.

PMID:
19704365
7.

Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.

Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG 2nd, Stemmer-Rachamimov A, Plotkin SR.

PLoS One. 2013;8(3):e59941. doi: 10.1371/journal.pone.0059941. Epub 2013 Mar 21.

8.

Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2.

Tysome JR, Macfarlane R, Durie-Gair J, Donnelly N, Mannion R, Knight R, Harris F, Vanat ZH, Tam YC, Burton K, Hensiek A, Raymond FL, Moffat DA, Axon PR.

Otol Neurotol. 2012 Apr;33(3):466-72. doi: 10.1097/MAO.0b013e318248eaaa.

PMID:
22334163
9.

Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.

Eminowicz GK, Raman R, Conibear J, Plowman PN.

J Laryngol Otol. 2012 Jan;126(1):79-82. doi: 10.1017/S0022215111002805. Epub 2011 Oct 18.

PMID:
22004800
10.

The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.

Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF.

Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3627-33. doi: 10.1007/s00405-014-3398-3. Epub 2014 Nov 25.

PMID:
25421643
11.

Hearing changes after diagnosis in neurofibromatosis type 2.

Masuda A, Fisher LM, Oppenheimer ML, Iqbal Z, Slattery WH; Natural History Consortium.

Otol Neurotol. 2004 Mar;25(2):150-4.

PMID:
15021775
12.

Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.

Meijer OW, Vandertop WP, Lagerwaard FJ, Slotman BJ.

Neurosurgery. 2008 May;62(5 Suppl):A37-42; discussion A42-3. doi: 10.1227/01.neu.0000325935.23852.9d.

PMID:
18580779
13.

Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.

Plotkin SR, Merker VL, Muzikansky A, Barker FG 2nd, Slattery W 3rd.

Otol Neurotol. 2014 Jan;35(1):e50-6. doi: 10.1097/MAO.0000000000000239.

PMID:
24335938
14.

Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma.

Lustig LR, Yeagle J, Driscoll CL, Blevins N, Francis H, Niparko JK.

Otol Neurotol. 2006 Jun;27(4):512-8.

PMID:
16791043
15.

Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.

Sponghini AP, Platini F, Rondonotti D, Soffietti R.

Tumori. 2015 Nov 14;101(6):e167-70. doi: 10.5301/tj.5000313.

PMID:
26108240
16.

Hearing improvement after bevacizumab for neurofibromatosis type 2.

Diao JS, Xia WS, Guo SZ.

N Engl J Med. 2009 Oct 29;361(18):1810; author reply 1810-1. No abstract available.

PMID:
19877310
17.

Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.

Choi JW, Lee JY, Phi JH, Wang KC, Chung HT, Paek SH, Kim DG, Park SH, Kim SK.

J Neurosurg Pediatr. 2014 Jun;13(6):650-7. doi: 10.3171/2014.3.PEDS13455. Epub 2014 Apr 11.

PMID:
24724714
18.

Middle fossa decompression for hearing preservation: a review of institutional results and indications.

Slattery WH, Hoa M, Bonne N, Friedman RA, Schwartz MS, Fisher LM, Brackmann DE.

Otol Neurotol. 2011 Aug;32(6):1017-24. doi: 10.1097/MAO.0b013e3182267eb7.

PMID:
21725256
19.

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, Hochman T, Goldberg JD, Koch KM, Golfinos JG, Roland JT, Allen JC.

Neuro Oncol. 2012 Sep;14(9):1163-70. doi: 10.1093/neuonc/nos146. Epub 2012 Jul 27.

20.

Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.

Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1197-204. doi: 10.1007/s00280-014-2456-2. Epub 2014 Apr 8.

PMID:
24710627

Supplemental Content

Support Center